Head and neck cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• COX-2 0
• LAG-3 2
• TROP2 5
• CD47 1
• EZH2 0
• MEK 0
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDCR · F31

  Investigating the impact of radiation therapy on oral squamous cell carcinoma microenvironment via non-classical class I major histocompatibility complex HLA-E

  University of California at Davis· Davis, United States· US$43,748 awarded in fiscal year 2026· until Aug 2029

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, United States· US$77,580 awarded in fiscal year 2026· until Sept 2028

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, United States· US$768,308 awarded in fiscal year 2026· until Aug 2027

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, United States· US$684,832 awarded in fiscal year 2026· until Jul 2031

• NIH NIDCR · R01

  Advancing FTIR-based Multimodal Imaging with AI for Risk Stratification of Oral Precancer

  University of Missouri Kansas City· Kansas City, United States· US$527,533 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Nov 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, United Kingdom· EU contribution €2,273,033· until May 2031

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Netherlands· EU contribution €2,498,319· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, France· EU contribution €7,248,398· until May 2030· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, France· EU contribution €7,999,120· until Nov 2028· 4 countries

10 of 564 running projects, newest first. Listed amounts together: US$326.5m + €36.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 307
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• Myeloid-derived suppressor cells in anaplastic thyroid carcinoma: insights from prospective immune profiling and implications for targeted immunotherapy.

  J Clin Pathol, Aug 2026

• Molecular-level insights into the therapeutic potential of lidocaine: effects on proliferation, autophagy, and cellular impedance in human oral cells.

  BMC Oral Health, Jun 2026

• Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma.

  Sci Rep, Jun 2026

• Azoxystrobin induces mitochondrial apoptosis by inhibiting cytochrome b Qo site of mitochondrial complex Ⅲ in oral leukoplakia cells and a mouse model.

  Arch Oral Biol, May 2026

• Flow-cytometric profiling of large extracellular vesicles as immunophenotypic biomarkers in head and neck squamous cell carcinoma.

  Cancer Immunol Immunother, May 2026

• Siglec expression in sentinel lymph nodes in patients with oral squamous cell carcinoma.

  Eur Arch Otorhinolaryngol, May 2026

• CXCR4+ cells in NPC tumor sphere have metastatic potential.

  Braz J Otorhinolaryngol, Mar 2026

• Blue light photobiomodulation attenuates aggressiveness and stemness features in oral squamous carcinoma cells.

  Arch Oral Biol, Mar 2026

• Chimeric RNAs as Novel Neoantigens for Extracellular Vesicles-Based Vaccines Against Cancer.

  Methods Mol Biol, Jan 2026

• DNA damage and cell death in human oral squamous cell carcinoma cells: The potential biological effects of cannabidiol.

  Arch Oral Biol, Oct 2024

See which targets of this disease your abstract mentions, and go to the people working on them.